The Use of Real-World Evidence for Decision-Making: Next Steps to Develop HTA Guidance

October 27, 2021
15:00-16:30 CET
Online

In this webinar organized by the RWE4Decisions multi-stakeholder initiative, consideration will be given to methodological recommendations on generation and use of real-world evidence (RWE) in pricing and reimbursement decision-making with a view to identifying what steps need to be taken to align on the way forwards. Guidance can act as a roadmap to generate high-quality RWE, to enable researchers and manufacturers to have a clear understanding of how it will be evaluated and for decision-makers to assess the completeness of their own RWE guidance.

Programme

15h00 – 15h05

Welcome

Diane Kleinermans

President of the Commission of Drugs Reimbursement, INAMI-RIZIV

15h05 – 15h20

Presentation: Developing comprehensive guidance to drive the use of RWE for decision-making

Páll Jónsson

Programme Director – Data, National Institute for Health and Care Excellence (NICE) and GetRealInstitute

15h20 – 15h35

Presentation: Four pillars to share comprehensive RWE guidance for HTA/Payers – building on existing work

Karen Facey

Consultant to RWE4Decisions

15h35 – 15h40

Q&A session

15h40 – 16h25

Panel discussion: What’s needed to create guidance on high-quality RWE for use in HTA/Payer decision-making

Cláudia Furtado

Head of the HTA, Pricing and Reimbursement Division and Information and Strategic Planning Division, National Authority for Medicines and Health Products (INFARMED) (Portugal)

Anja Schiel

Senior Advisor, Norwegian Medicines Agency (NOMA) (Norway) and Chair of the Scientific Advice Working Party, European Medicines Agency (EMA)

Aisling O’Leary

Chief Pharmacist, National Centre for Pharmacoeconomic Evaluations (NCPE) (Ireland)

Niklas Hedberg

Chief Pharmacist, Swedish Dental and Pharmaceuticals Benefits Agency, (TLV) (Sweden)

Background

After opening presentations about existing methodological guidance and new initiatives, our panel of national decision-makers will consider the opportunities for collaboration to accelerate progress towards the generation of comprehensive guidance for RWE quality and transparency in HTA/Payer pricing and reimbursement decisions.

Other past events

Public Webinar: From Policy to Practice: EHDS Implementation to Support Better Real-World Evidence for HTA/Payers

April 9, 2025
15:00-16:30 CEST
Online

RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA

November 14, 2024
09:00-13:00 CET
Hybrid

Public Webinar: HTA/Payer Collaboration in the Nordics: The Role of Real-World Evidence

October 23, 2024
15:00-16:00 CEST
Online